Home » Stocks » AVDL

Avadel Pharmaceuticals PLC (AVDL)

Stock Price: $7.81 USD 0.20 (2.63%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $7.95 +0.14 (1.79%) Jul 26, 6:46 PM
Market Cap 435.73M
Revenue (ttm) 10.09M
Net Income (ttm) -5.55M
Shares Out 58.49M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $7.81
Previous Close $7.61
Change ($) 0.20
Change (%) 2.63%
Day's Open 7.70
Day's Range 7.31 - 8.08
Day's Volume 360,732
52-Week Range 4.83 - 10.33

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN, Ireland, July 07, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

2 weeks ago - GlobeNewsWire

DUBLIN, Ireland, June 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

1 month ago - GlobeNewsWire

DUBLIN, Ireland, June 03, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

1 month ago - GlobeNewsWire

Bolsters team with addition of established biopharma industry leaders in advance of anticipated regulatory approval and commercialization of once-nightly FT218 for narcolepsy Bolsters team with addition...

1 month ago - GlobeNewsWire

DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tre...

2 months ago - GlobeNewsWire

DUBLIN, Ireland, May 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designe...

2 months ago - GlobeNewsWire

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate desig...

2 months ago - GlobeNewsWire

DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON-S...

3 months ago - GlobeNewsWire

FT218 assigned PDUFA target action date of October 15, 2021 FT218 assigned PDUFA target action date of October 15, 2021

4 months ago - GlobeNewsWire

DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate design...

5 months ago - GlobeNewsWire

DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

5 months ago - GlobeNewsWire

Investors who target growth may want to consider the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year basis.

Other stocks mentioned: ADUS, IRS
7 months ago - GuruFocus

DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate design...

7 months ago - GlobeNewsWire

DUBLIN, Ireland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

8 months ago - GlobeNewsWire

DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

8 months ago - GlobeNewsWire

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Avadel Pharmaceuticals plc's (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

DUBLIN, Ireland, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate design...

8 months ago - GlobeNewsWire

DUBLIN, Ireland, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate design...

9 months ago - GlobeNewsWire

DUBLIN, Ireland, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, tod...

10 months ago - GlobeNewsWire

DUBLIN, Ireland, Sept. 14, 2020 (GLOBE NEWSWIRE) --  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate de...

10 months ago - GlobeNewsWire

DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, tod...

10 months ago - GlobeNewsWire

Avadel (AVDL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Shares of Avadel Pharmaceuticals (NASDAQ:AVDL) decreased 1.3% in pre-market trading after the company reported Q2 results.

11 months ago - Benzinga

DUBLIN, Ireland, July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10, ...

11 months ago - GlobeNewsWire

DUBLIN, Ireland, July 13, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, toda...

1 year ago - GlobeNewsWire

DUBLIN, Ireland, July 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for ...

1 year ago - GlobeNewsWire

DUBLIN, Ireland, June 08, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for t...

1 year ago - GlobeNewsWire

Avadel (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

One is a blue chip, the other a small-cap, but both are innovators with significant growth opportunities.

Other stocks mentioned: REGN
1 year ago - The Motley Fool

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Avadel's (AVDL) first quarter 2020 earnings and revenues surpass expectations.

1 year ago - Zacks Investment Research

DUBLIN, Ireland, April 28, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for...

1 year ago - GlobeNewsWire

On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.

1 year ago - Zacks Investment Research

DUBLIN, Ireland, April 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for...

1 year ago - GlobeNewsWire

Investors are excited about positive late-stage results for its narcolepsy drug.

1 year ago - The Motley Fool

In the current session, Avadel Pharmaceuticals Inc. (NASDAQ: AVDL) is trading at $12.95, after a 31.74% increase.

1 year ago - Benzinga

As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.

1 year ago - Zacks Investment Research

Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Avadel Pharmaceuticals (AVDL) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Topline data from the REST-ON study expected in Q2 2020 Topline data from the REST-ON study expected in Q2 2020

1 year ago - GlobeNewsWire

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

A Seldom Discussed Detail Reignites The Avadel Bullish Case

1 year ago - Seeking Alpha

Can these high-flying biotech stocks keep up their sizzling momentum?

Other stocks mentioned: ABEO, RCUS
1 year ago - The Motley Fool

An infusion of cash is just what the doctor ordered.

1 year ago - The Motley Fool

DUBLIN, Ireland, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for ...

1 year ago - GlobeNewsWire

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

Though international markets trailed the U.S. market in 2019, there are hidden gems that crushed the S&P 500 this year on stock-specific strength.

Other stocks mentioned: EDU, RCEL, SBGL, VIPS
1 year ago - Zacks Investment Research

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

About AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jun 7, 1996
CEO
Gregory Divis
Employees
32
Stock Exchange
NASDAQ
Ticker Symbol
AVDL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for AVDL stock is "Strong Buy." The 12-month stock price forecast is 18.61, which is an increase of 138.28% from the latest price.

Price Target
$18.61
(138.28% upside)
Analyst Consensus: Strong Buy